FDA agrees wider use of BioMarin’s BRINEURA for CLN2
The US FDA has expanded approval to BioMarin Pharmaceutical's BRINEURA to include children aged below three years with neuronal CLN2.
The US FDA has expanded approval to BioMarin Pharmaceutical's BRINEURA to include children aged below three years with neuronal CLN2.
What's Your Reaction?
